## **EXHIBIT 29**

|    | Page 1  |
|----|---|
| 1  | IN THE UNITED STATES DISTRICT COURT                 |
| 2  | FOR THE NORTHERN DISTRICT OF OHIO  EASTERN DIVISION |
| 3  |   |
| 4  |   |
| 5  | IN RE: NATIONAL PRESCRIPTION MDL No. 2804           |
|    | OPIATE LITIGATION Case No. 17-md-2804               |
| 6  |   |
| 7  | This document relates to: Judge Dan                 |
|    | Aaron Polster                                       |
| 8  |   |
|    | The County of Cuyahoga v. Purdue                    |
| 9  | Pharma, L.P., et al.                                |
|    | Case No. 17-0P-45005                                |
| 10 |   |
|    | City of Cleveland, Ohio vs. Purdue                  |
| 11 | Pharma, L.P., et al.                                |
|    | Case No. 18-0P-45132                                |
| 12 |   |
|    | The County of Summit, Ohio,                         |
| 13 | et al. v. Purdue Pharma, L.P.,                      |
|    | et al.  |
| 14 | Case No. 18-0P-45090                                |
|    |   |
| 15 |   |
| 16 |   |
| 17 | VOLUME I  |
| 18 | Videotaped Deposition of Kyle J. Wright             |
| 19 | Washington, D.C.                                    |
| 20 | February 28, 2019                                   |
| 21 | 9:33 a.m.   |
| 22 |   |
| 23 |   |
| 24 | Reported by: Bonnie L. Russo                        |
| 25 | Job No. 3244302                                     |
| -  |   |

Page 68 1 manufacturer would have visibility at the doctor-patient level? Under certain circumstances. 3 Α. Because the manufacturers could be ordering 4 5 particular products and obtain them directly from a manufacturer. 6 7 There were also programs where they got rebates and other things like this. And so 8 9 they also knew. There were certain limited 10 circumstances in which manufacturer community 11 could -- community could see downstream. It's 12 limited. 13 Ο. Limited circumstances? 14 Yes, ma'am. Α. Okay. And would distributors have 15 Ο. 16 visibility or know about the doctor-patient 17 relationships? MR. SHKOLNIK: Objection to form. 18 19 MR. MIGLIORI: Objection to form. 20 THE WITNESS: Not in totality. 21 BY MS. MAINIGI: 2.2 Ο. So to be clear, a distributor would 23 not know anything about the doctor-patient 24 relationship, correct? 2.5 MR. MIGLIORI: Objection.

Veritext Legal Solutions
www.veritext.com
888-391-3376

Page 69 1 THE WITNESS: On a specific 2. doctor-patient relationship, no. 3 MS. McCLURE: Can we go off the record for a minute. The live feed stopped 4 5 working a few questions ago. 6 THE VIDEOGRAPHER: We are going off 7 the record. This is the end of Media Unit No. 1. 8 9 The time is 10:37. 10 (A short recess was taken.) 11 THE VIDEOGRAPHER: We are going back 12 on the record. 13 This is the beginning of Media Unit 2. 14 The time is 10:48. 15 16 You may proceed, Counsel. 17 BY MS. MAINIGI: 18 Mr. Wright, you recall mentioning Q. 19 earlier that you were transferred to DEA 20 headquarters around 2005, I think April Fool's Day 2005, right? 21 2.2 Α. Yes. 23 Now, at the time that you moved over Ο. 24 to DEA headquarters, was there a system in 2.5 place called the Excessive Purchase Program?

Veritext Legal Solutions
www.veritext.com

888-391-3376